Jane Street’s Citius Oncology CTOR Stock Holding History

Jane Street’s Portfolio CTOR Stock Details CTOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-106,970	Closed	-$465K	–	12035
2025 Q2	$465K	Buy	+106,970	New	+$125K	﹤0.01%	7060

Other funds holding CTOR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Jane Street's CTOR Position: Q3 2025 in Review

Jane Street sold out of Citius Oncology (CTOR) in Q3 2025, closing a stake of 106,970 shares — an estimated $465K sold.

Jane Street first reported a position in CTOR in Q2 2025 and held it in 1 quarter. The position peaked at $465K in Q2 2025. 16 funds tracked by Wall St. Rank hold CTOR as of Q3 2025.

Jane Street reported no remaining Citius Oncology position as of Q3 2025 after selling out during the quarter.
Jane Street sold 106,970 Citius Oncology shares in Q3 2025, an estimated $465K.
Jane Street first reported a position in Citius Oncology in Q2 2025 and held it in 1 quarter.
Jane Street's Citius Oncology position peaked at $465K in Q2 2025.
16 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.